Clinical case of somatotropinoma in a patient with morbid obesity

Obesity is a chronic endocrine disorder characterized by excessive adipose tissue and associated with development of various adverse metabolic processes in the body.

This case report highlights a clinical case involving the detection of a hormonally active pituitary microadenoma in a patient with morbid obesity and reproductive dysfunction. The application of a described multidisciplinary approach led to the timely verification of the underlying condition and the routing of the patient to a specialized center, which prevented the development of complications associated with acromegaly and improved the patient’s quality of life. Restoration of cyclic ovarian function following neurosurgical intervention and regression of adipose mass resulted in clinical improvement of well-being and the occurrence of pregnancy. Currently, the patient is under the care and observation of a multidisciplinary team of specialists.

1. Abreu A, Tovar AP, Castellanos R, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19(4):448-457. doi: https://doi.org/10.1007/s11102-016-0725-2

2. Zajdieva YaZ, Rifatova AV. Akromegaliya u zhenshin: vzglyad ginekologa. Rossijskij vestnik akushera-ginekologa. 2014;14(3):38-42. (In Russ.)

3. Popescu AD, Carsote M, Valea A, et al. Approach of Acromegaly during Pregnancy. Diagnostics (Basel). 2022;12(11):2669. Published 2022 Nov 2. doi: https://doi.org/10.3390/diagnostics12112669

4. Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175(3):181-190. doi: https://doi.org/10.1530/EJE-16-0117

5. Park KH, Lee EJ, Seo GH, Ku CR. Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly. J Clin Endocrinol Metab. 2020;105(4):dgz317. doi: https://doi.org/10.1210/clinem/dgz317

6. Guo X, Fu H, Pang H, Xing B. Risk of left ventricular hypertrophy and diastolic and systolic dysfunction in Acromegaly: A meta-analysis. J Clin Neurosci. 2018;48:28-33. doi: https://doi.org/10.1016/j.jocn.2017.10.067

7. Shi S, Zhang L, Yu Y, Wang C, Li J. Acromegaly and non-parathyroid hormone-dependent hypercalcemia: a case report and literature review. BMC Endocr Disord. 2021;21(1):90. Published 2021 May 1. doi: https://doi.org/10.1186/s12902-021-00756-z

8. Khan SA, Ram N, Masood MQ. Patterns of Abnormal Glucose Metabolism in Acromegaly and Impact of Treatment Modalities on Glucose Metabolism. Cureus. 2021;13(3):e13852. Published 2021 Mar 12. doi: https://doi.org/10.7759/cureus.13852

9. de Silva T, Cosentino G, Ganji S, Riera-Gonzalez A, Hsia DS. Endocrine Causes of Hypertension. Curr Hypertens Rep. 2020;22(11):97. Published 2020 Oct 20. doi: https://doi.org/10.1007/s11906-020-01108-3

10. Carroll PV, Joshi MN. Acromegaly. Endotext [Internet]. MDText. com, Inc., 2022

11. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4-9. doi: https://doi.org/10.1007/s11102-016-0754-x

12. Ganz JC. Pituitary adenomas. Prog Brain Res. 2022;268(1):191-215. doi: https://doi.org/10.1016/bs.pbr.2021.10.032

13. Ambrosio MR, Gagliardi I, Chiloiro S, et al. Acromegaly in the elderly patients. Endocrine. 2020;68(1):16-31. doi: https://doi.org/10.1007/s12020-020-02206-7

14. Lamas C, García-Martínez A, Cámara R, Fajardo Montanana C, Viguera L, Aranda I. Silent somatotropinomas. Minerva Endocrinol. 2019;44(2):137-142. doi: https://doi.org/10.23736/S0391-1977.18.02946-2

15. Esposito D, Ragnarsson O, Granfeldt D, Marlow T, Johannsson G, Olsson DS. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol. 2018;178(5):459-469. doi: https://doi.org/10.1530/EJE-18-0015

16. Przhiyalkovskaya EG, Mokrysheva NG, Troshina EA, et al. Guidelines on diagnostics and treatment of acromegaly (draft). Obesity and metabolism. 2024;21(2):215-249. (In Russ.). doi: https://doi.org/10.14341/omet13153

17. Freda PU. The acromegaly lipodystrophy. Front Endocrinol (Lausanne). 2022;13:933039. Published 2022 Sep 13. doi: https://doi.org/10.3389/fendo.2022.933039

18. Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends Endocrinol Metab. 2016;27(7):470-483. doi: https://doi.org/10.1016/j.tem.2016.04.014

19. Olarescu NC, Bollerslev J. The Impact of Adipose Tissue on Insulin Resistance in Acromegaly. Trends Endocrinol Metab. 2016;27(4):226-237. doi: https://doi.org/10.1016/j.tem.2016.02.005

20. Reid TJ, Jin Z, Shen W, et al. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary. 2015;18(6):808-819. doi: https://doi.org/10.1007/s11102-015-0657-2

21. Calan M, Demirpence M. Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly. Hormones (Athens). 2019;18(4):435-442. doi: https://doi.org/10.1007/s42000-019-00151-3

22. Ciresi A, Amato MC, Pizzolanti G, Giordano C. Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations. Growth Horm IGF Res. 2015;25(5):240-246. doi: https://doi.org/10.1016/j.ghir.2015.07.002

23. Wolters TLC, Netea MG, Riksen NP, et al. Acromegaly, inflammation and cardiovascular disease: a review. Rev Endocr Metab Disord. 2020;21(4):547-568. doi: https://doi.org/10.1007/s11154-020-09560-x

24. Lopes AA, Albuquerque L, Fontes M, Rego D, Bandeira F. Body Composition in Acromegaly According to Disease Activity - Performance of Dual X-Ray Absorptiometry and Multifrequency Bioelectrical Impedance Analysis. Front Endocrinol (Lausanne). 2022;13:866099. Published 2022 May 18. doi: https://doi.org/10.3389/fendo.2022.866099

25. Khiyami A, Mehrotra N, Venugopal S, et al. IGF-1 is positively associated with BMI in patients with acromegaly. Pituitary. 2023;26(2):221-226. doi: https://doi.org/10.1007/s11102-023-01307-6

26. Vorotnikova SY, Pigarova EA, Dzeranova LK. Metabolicheskie effekty gormona rosta. Obesity and metabolism. 2011;8(4):55-59

27. Schmid C, Goede DL, Hauser RS, Brändle M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136(15-16):254-258. doi: https://doi.org/10.4414/smw.2006.10955

28. Itriyeva K. The effects of obesity on the menstrual cycle. Curr Probl Pediatr Adolesc Health Care. 2022;52(8):101241. doi: https://doi.org/10.1016/j.cppeds.2022.101241

29. Fielder S, Nickkho-Amiry M, Seif MW. Obesity and menstrual disorders. Best Pract Res Clin Obstet Gynaecol. 2023;89:102343. doi: https://doi.org/10.1016/j.bpobgyn.2023.102343

30. Pirchio R, Auriemma RS, Grasso LFS, et al. Fertility in Acromegaly: A Single-Center Experience of Female Patients During Active Disease and After Disease Remission. J Clin Endocrinol Metab. 2023;108(8):e583-e593. doi: https://doi.org/10.1210/clinem/dgad042

31. Tomczyk K, Rzymski P, Woźniak J, Wilczak M. Pregnancy in a woman with acromegaly after transsphenoidal partial resection of pituitary macroadenoma - a case report. Pol Merkur Lekarski. 2017;43(258):268-271

32. Caron P, Broussaud S, Bertherat J, et al. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab. 2010;95(10):4680-4687. doi: https://doi.org/10.1210/jc.2009-2331